Vein Center of Cincinnati<\/a>, said he began a journey to better health after dealing with heaviness in his feet and fatigue. \u201cMy feet were heavy, you know, and very hard to move in the mornings,\u201d Ramon said.<\/p>\nGLP-1 weight loss medications are helping some patients see improvements beyond the number on the scale, including relief from symptoms tied to vascular problems and inflammation, according to a Cincinnati vascular surgeon and one of his patients. (WKRC, Provided)<\/p>\n<\/p>\n
Ramon said he was overweight at the time and often felt drained. \u201cI was eating larger portion meals at that time. I would get tired a lot, loss of energy, and that was my biggest ordeal,\u201d he said.<\/p>\n
A few months ago, Ramon met Dr. Andrew Hearn, a vascular surgeon at the Vein Center of Cincinnati, who treated Ramon\u2019s varicose veins. Hearn said patients with vein problems often experience symptoms such as swelling or heaviness in the legs and can have mobility issues.<\/p>\n
Hearn said his approach can include addressing vein health, lymphatic issues and metabolism, including recommending peptides for some patients with chronic leg pain and swelling. \u201cWe\u2019re addressing the quality or health of their veins. We\u2019re addressing their lymphatics, but we\u2019re also addressing their metabolism and prescribing and recommending peptides for patients that this chronic leg pain and swelling,\u201d Hearn said.<\/p>\n
Peptides are chains of amino acids in the body, and different types are used for health and wellness. Ozempic is a GLP-1 peptide that came out in 2017 and has been widely used for weight loss. Hearn said GLP-1 medications can help curb cravings for unhealthy foods. \u201cIt helps the brain realize what\u2019s healthy food and what is like the processed junk food. Once you\u2019re on a GLP-1 automatically, there\u2019s craving that is stopped on the bad foods,\u201d he said.<\/p>\n
Hearn said getting a patient\u2019s metabolism \u201cin a good place\u201d can also help vascular issues. The FDA approved another GLP-1 peptide, Zepbound, in 2023. Researchers are also studying GLP-1 medications not only for weight loss, but for treating other chronic conditions.<\/p>\n
\u201cNow we\u2019re finding patients with joint pain, a lot of inflammatory problems are indirectly, they\u2019re no longer having their back pain, their knee pain is gone,\u201d Hearn said.<\/p>\n
Ramon said he feels great since starting the medication and has been able to avoid foods he once relied on. \u201cI\u2019ve done away with bread and potato chips. I don\u2019t, I was a huge fan of those. Because that was my go-to. Now, since I cut away those carbs, I think, you know, my body has definitely gone to a better route,\u201d Ramon said.<\/p>\n
The Vein Center of Cincinnati encouraged people with leg pain or swelling, or those seeking more information on GLP-1s, to contact the clinic<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"CINCINNATI (WKRC) – GLP-1 weight loss medications are helping some patients see improvements beyond the number on the…\n","protected":false},"author":2,"featured_media":1163691,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[105,4326,16,15],"class_list":["post-1163690","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117141323654487254","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1163690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1163690"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1163690\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1163691"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1163690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1163690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1163690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}